Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation



    
    Combination of industry-leading services with unique QTRAP(R) technology

    
    MONTREAL, May 28 /CNW/ -- Caprion Proteomics Inc. today announced that it
is working with Applied Biosystems, a division of Life Technologies
Corporation (Nasdaq:   LIFE), to accelerate the verification and validation of
protein biomarker candidates toward potential use in clinical settings. 
Caprion is extending its leadership in mass spectrometry-based biomarker
services by applying QTRAP(R) technology for the development and deployment of
Multiple Reaction Monitoring (MRM) assays to advance the clinical validation
of biomarker candidates. Caprion will discuss this scientific initiative at
the Biomarker World Congress 2009 conference this week in Philadelphia.

    Discovery of a significant number of biomarker candidates in academia and
industry has created the need to verify and validate these markers in
large-scale projects to determine the most promising for clinical development.
 Caprion specializes in large-scale studies of biomarkers as a service for
pharmaceutical and biotechnology companies as well as for government agencies.
 Applied Biosystems provides mass spectrometry technology that complements
Caprion's long-standing strength in biomarker discovery to address the need to
advance candidates along the biomarker continuum.

    QTRAP technology, which was developed by the Applied Biosystems/MDS
Analytical Technologies joint venture, enables integrated quantitative and
qualitative analysis through the MIDAS workflow for fast MRM assay development
and accurate quantitative results.  This makes it the technology of choice for
Caprion to expand its quantitative capabilities into this rapidly emerging
field.

    For the many instances where there are no available commercial assays for
a given set of protein biomarker candidates, the MRM technique offers a faster
and more cost-effective alternative to established enzyme-linked immunosorbant
assay (ELISA) development approaches.  MRM assays can be developed within a
matter of weeks and enables the quantitative parallel tracking of large
numbers of biomarker candidates through a multiplex high-throughput format. 
This technique, therefore, has the potential to unlock significant value from
the scores of genomics, proteomics and other biomarker candidates that have
not yet progressed to the validation stage.

    The mass-spectrometry-based technique can also prove advantageous in
cases where specificity is required and specific post translational
modifications or protein isoforms are critical to monitor but difficult to
differentiate by antibody techniques.

    This joint effort is another example of both companies working with
industry leaders to help fulfill the promise of proteomics for a variety of
applications, such as personalized medicine, clinical pharmacology and
diagnostics.  By extending its best-in-class service for biomarker advancement
beyond the discovery phase into validation and assay development, Caprion is
building on its momentum created by its exclusive strategic alliance on
proteomic biomarkers with Covance Inc., as well as its vast experience in the
field, including work on more than 30 biomarker studies for 20 large
pharmaceutical and biotech clients, plus two large multi-year, multi-million
dollar bio-defense contracts for the NIH-NIAID.

    "With the advent of MRM assays, which we have now put into practice with
the help of QTRAP technology, we are changing the way scientists view
biomarker research by offering superior services that make it more
cost-effective and productive for pharmaceutical and biotech organizations to
not only undertake biomarker programs, but to carry them through to their
intended clinical use," said Daniel Chelsky, Chief Scientific Officer of
Caprion.  "We believe that the availability and use of MRM instrumentation and
assays will expand the market for biomarker discovery, verification and
validation."

    David Hicks, Senior Director of Applied Biosystems' Pharmaceutical and
Proteomics business, added, "Our initiative for protein biomarker verification
and validation puts a priority on teaming up with other leading scientists who
are committed to the same goal of accelerating the progress of biomarkers. 
The technology has evolved to the point where working with organizations, such
as Caprion, is more rapidly unlocking the potential of protein biomarkers and
helping to advance the proteomics field."
    

    About Caprion Proteomics
    
    Caprion Proteomics is the leading provider of proteomics based services
to the pharmaceutical and biotech industries.  Caprion's proprietary
proteomics discovery technology, CellCarta(R), is a gel-free, label-free mass
spectrometry platform that enables a comprehensive, quantitative and robust
measurement of the protein expression differences across large sets of
biological samples. Caprion has been providing biomarker and target
identification services since 2002, performing more than 30 large-scale
biomarker projects for pharmaceutical industry clients such as Pfizer, Johnson
& Johnson, Abbott Laboratories, Biogen Idec, Daiichi-Sankyo,
Mitsubishi-Tanabe,  Wyeth, AstraZeneca, Merck, Boehringer Ingelheim,  ICOS,
Bayer-Schering , EMD-Serono, Vertex, DebioPharm and Transgene. Caprion also
has been awarded two consecutive 5-year US$13 million contracts for Biodefense
proteomics research in the area of infectious diseases with the NIH-NIAID.
Caprion recently entered into a worldwide strategic marketing and distribution
alliance for biomarker services with Covance Inc. which also involved the
purchase by Covance of a minority equity stake in the company. Caprion
Proteomics, a privately-held company, is majority owned by Great Point
Partners, LP.  For more information, please visit: www.caprion.com.

    Copyright 2009.  QTRAP is a registered trademark of Applied
Biosystems/MDS Analytical Technologies, a joint venture between Applied
Biosystems LLC and MDS Inc.


    
    Caprion Proteomics Inc.
    Media
    Didier Jean-Francois
    Director of Marketing and Business Development
    Caprion Proteomics Inc.,
    (514) 228-3625
    dfrancois@caprion.com
    

    
    Life Technologies
    Media
    Anthony Petrucci
    Public Relations
    508.383.7961
    anthony.petrucci@lifetech.com



    




For further information:

For further information: Didier Jean-Francois, Director of Marketing and
Business Development of Caprion Proteomics Inc., +1-514-228-3625,
dfrancois@caprion.com, or Anthony Petrucci of Life Technologies, Public
Relations, +1-508-383-7961, anthony.petrucci@lifetech.com Web Site:
http://www.caprion.com

Organization Profile

CAPRION PROTEOMICS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890